Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Glioblastoma 30Carcinoma, Non-Small-Cell Lung 30Lung Neoplasms 23Head and Neck Neoplasms 21Squamous Cell Carcinoma of Head and Neck 15Lymphoma 15Gliosarcoma 15Central Nervous System Neoplasms 14Sarcoma 12Esophageal Neoplasms 12Rectal Neoplasms 10Glioma 10Leukemia 9Breast Neoplasms 9Brain Neoplasms 9Prostatic Neoplasms 8Pancreatic Neoplasms 8Lymphoma, Follicular 7Esophageal Squamous Cell Carcinoma 7Neoplasms 6Melanoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Uterine Cervical Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Astrocytoma 5

Interventions

pembrolizumab 3Docetaxel 3Cisplatin 3Erlotinib Hydrochloride 2Cetuximab 2Carboplatin 2spartalizumab 1ixabepilone 1entrectinib 1Vorinostat 1Tablets 1Radiotherapy 1Radiosurgery 1RC48 antibody 1Paclitaxel 1Nivolumab 1NVP-BKM120 1Ipilimumab 1Gemcitabine 1Fluorodeoxyglucose F18 1FPP(RGD)2 1Everolimus 1Epirubicin 1Combined Modality Therapy 1Chemoprevention 1Capecitabine 1CTLA-4 Antigen 1Bevacizumab 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Salivary Gland Neoplasms × Radiotherapy × Clear all
NCT00003251 2013-12-04

Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Radiation Injuries, Salivary Gland Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡